Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYTH2 | Q99418 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 5/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.49 |
| ▸ | IL1RN | P18510 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4955646 | 0.86 | CYTH2 (0.64) | CYTH2MEN1KMT2ACRHBPCRHR2 | |
| SCHEMBL22024972 | 0.84 | PKM (0.69) | CYTH2MEN1KMT2AGAALMNA | |
| SCHEMBL22024973 | 0.83 | PKM (0.70) | MEN1KMT2AGAALMNASMN1; SMN2 | |
| SCHEMBL30343351 | 0.80 | PKM (0.69) | CYTH2MEN1KMT2ACRHBPCRHR2 | |
| SCHEMBL7577338 | 0.80 | PKM (0.69) | CYTH2MEN1KMT2ACRHBPCRHR2 | |
| SCHEMBL14606818 | 0.76 | CYTH2 (0.77) | CYTH2MEN1KMT2AGAALMNA | |
| SCHEMBL7572838 | 0.76 | PKM (0.67) | CYTH2MEN1KMT2AGAALMNA | |
| SCHEMBL10572974 | 0.76 | FFAR4 (0.68) | CYTH2MEN1KMT2AGAALMNA | |
| SCHEMBL13997280 | 0.76 | CYTH2 (0.71) | CYTH2MEN1KMT2AGAALMNA | |
| SCHEMBL20812928 | 0.75 | KMT2A (0.70) | MEN1KMT2AGAALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | XIAMEN UNIVERSITY (CN) | 2022-06-07 | — | — | US | disclosed |
| EP-3663293-A1 | SUBSTITUTED PENTA- AND HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | Xiamen University (CN) | 2020-06-10 | — | — | EP | disclosed |
| US-20200165246-A1 | SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | XIAMEN UNIVERSITY (CN) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | PIKFYVE, PIK3CA, PIK3C2A | CYTH2 2602/4885MEN1 1829/4885KMT2A 1663/4885 |
| US-20200165246-A1 | SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | PIKFYVE, PIK3CA, PIK3C2A | CYTH2 2602/4885MEN1 1829/4885KMT2A 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.